CGTN: China Makes Proposals for UN's Role in Post-Pandemic Era
22.9.2020 09:48:00 EEST | Business Wire | Press release
The United Nations, beginning with 51 signatories at the end of World War II, has now grown to be a 193-nation body. As it celebrates its 75th founding anniversary, the organization and multilateralism it represents are facing unprecedented challenges with the rise of unilateralism and protectionism.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005948/en/
The challenges are being compounded by COVID-19, which has infected more than 31 million people and taken over 960,000 lives worldwide.
"What kind of UN does the world need and what role should it play in the post-pandemic era?"
Chinese President Xi Jinping raised the question and made proposals on Monday when addressing the high-level meeting to commemorate the 75th anniversary of the UN via video link.
The UN should uphold justice as countries, regardless of their sizes, are equal and should respect each other, Xi said, noting that this is a requirement of the progress of the times and the most important principle in the UN Charter.
The organization should be committed to achieving shared growth through consultation and collaboration, he stressed, calling on countries around the world to maintain common security and share the fruits of development.
Xi called for increased representation and a louder voice for developing countries in the UN and upholding the purposes and principles of the UN Charter.
He said the UN should promote international cooperation and lead efforts to solve various problems in the world. It should advance security, development and human rights in a balanced manner and give more emphasis to development on its global agenda, he added.
Uphold multilateralism, enhance cooperation
"During the 75 years of the UN, the world has seen rapid progress of the human society, profound changes in international situations and fast development of multilateralism," the Chinese president said.
He reiterated China's commitment to multilateralism and determination to safeguard the international system with the UN at its core.
As the international community strives to find solutions to problems faced by mankind, "multilateralism" has been a buzzword during the 75th session of the UN General Assembly that opened last week.
UN Secretary-General Antonio Guterres urged world leaders to work together at a time when there is a surplus of multilateral challenges and a deficit of solutions. "The future we want, the United Nations we need, is reaffirming our collective commitment to multilateralism is under way," he said.
Indeed, the need for more – and more effective – multilateralism is well known, he said, stressing that national sovereignty – a pillar of the Charter of the United Nations – goes hand‑in‑hand with enhanced international cooperation, based on common values and shared responsibilities for progress.
Russian Foreign Minister Sergei Lavrov said the international community is becoming increasingly fragmented, adding that "this is largely attributable to the fact that some countries are meddling in the domestic affairs of other states and imposing unilateral sanctions."
"The world is tired of dividing lines, of separating states into friends and foes, and demands stepping up all-encompassing and inclusive mutual assistance and cooperation," he said.
German Chancellor Angela Merkel said the interests of individual member states had "too often" forced the UN to lag behind its ideals.
"Those who believe that they can get along better alone are mistaken. Our well-being is something that we share – our suffering too. We are one world," she told the General Assembly.
While customs and cultures may differ, cooperation requires unstinting efforts to overcome misunderstanding, and beyond that, to embrace respect, European Council President Charles Michel noted.
"It is not our rhetoric that will matter," he said, but rather, the collective actions taken to foster a better world.
The theme of this year's UN high-level sessions is "The Future We Want, the UN We Need: Reaffirming Our Collective Commitment to Multilateralism." It echoes Xi's consistent call to build a community with a shared future for mankind.
Meanwhile, 48 former UN and government officials from around the world released an open letter – "A Time for Renewal: Calling for a Strengthened Multilateral System" – last Friday, expressing their hope that the UN would be transformed into a "stronger, more accountable, inclusive multilateral system."
"There is an urgent need for an explicit recognition by global leaders that we are at a turning point and must act decisively to defend and rejuvenate multilateralism," they said, stressing that recovery from the COVID-19 pandemic needs national leadership and effective global cooperation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200921005948/en/
Contact information
Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
